Imperial College London
Portrait Picture

ProfessorNagyHabib

Faculty of Medicine, Department of Surgery & Cancer

Professor of Hepatobiliary Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 8574nagy.habib

 
 
//

Assistant

 

Mrs Benita White +44 (0)7960 986 387

 
//

Location

 

BN1/18 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kumar:2020:10.3390/vaccines8020247,
author = {Kumar, J and Habib, NAGY and Huang, KAI and Warwick, JANE and MAURO, P and ARASARADNAM, R},
doi = {10.3390/vaccines8020247},
journal = {Vaccines},
title = {Immunological basis of genesis of hepatocellular carcinoma: unique  challenges and potential opportunities through immunomodulation},
url = {http://dx.doi.org/10.3390/vaccines8020247},
volume = {8},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - A majority of hepatocellular carcinoma (HCC) develops in the setting of persistent chronic inflammation as immunological mechanisms have been shown to play a vital role in the initiation, growth and progression of tumours. The index review has been intended to highlight ongoing immunological changes in the hepatic parenchyma responsible for the genesis and progression of HCC. The in-situ vaccine effect of radiofrequency (RF) is through generation tumour-associated antigens (TAAs), following necrosis and apoptosis of tumour cells, which not only re-activates the antitumour immune response but can also act in synergism with checkpoint inhibitors to generate a superlative effect with intent to treat primary cancer and distant metastasis. An improved understanding of oncogenic responses of immune cells and their integration into signaling pathways of the tumour microenvironment will help in modulating the antitumour immune response. Finally, we analyzed contemporary literature and summarised the recent advances made in the field of targeted immunotherapy involving checkpoint inhibitors along with RF application with the intent to reinstate antitumour immunity and outline future directives in very early and early stages of HCC.
AU  - Kumar,J
AU  - Habib,NAGY
AU  - Huang,KAI
AU  - Warwick,JANE
AU  - MAURO,P
AU  - ARASARADNAM,R
DO  - 10.3390/vaccines8020247
PY  - 2020///
SN  - 2076-393X
TI  - Immunological basis of genesis of hepatocellular carcinoma: unique  challenges and potential opportunities through immunomodulation
T2  - Vaccines
UR  - http://dx.doi.org/10.3390/vaccines8020247
UR  - http://hdl.handle.net/10044/1/80667
VL  - 8
ER  -
Download